CoChat

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Autoimmunity associated with anti-tumor necrosis factor α treatment in Crohn’s disease: a prospective cohort study

Vermeire, Severine, Noman, Maja, Van Assche, Gert, Baert, Filip, Van Steen, Kristel, Esters, Nele, Joossens, Sofie, Bossuyt, Xavier, Rutgeerts, Paul · 2003 · Gastroenterology

Abstract

Background & aims Infliximab therapy is an effective approach to treating Crohn's disease. Development of antinuclear antibodies has been described in patients treated, but the size of the problem and the relationship with autoimmunity have not been investigated. We investigated the occurrence of antinuclear antibodies in 125 consecutive Crohn's disease patients and studied the relationship with symptoms of autoimmunity.Methods Autoantibodies and clinical data were investigated before and 1, 2, and 3 months after infliximab infusion. If antinuclear antibodies were > or =1:80, further study of double-stranded DNA, single-stranded DNA, histones, and ENA was performed.Results Cumulative antinuclear antibody incidence at 24 months was 71 of 125 (56.8%). Almost half of these patients developed antinuclear antibodies after the first infusion, and >75% became antinuclear antibody positive after fewer than 3 infusions. So far, only 15 of 71 patients have become seronegative, after a median of 12 months. Of 43 antinuclear antibody-positive patients who were further subtyped, 14 of 43 (32.6%) had double-stranded DNA, 17 (39.5%) had single-stranded DNA, 9 (20.9%) had antihistone, and 0% were ENA positive. Two patients (both antihistone and double-stranded DNA positive) developed drug-induced lupus without major organ damage, and 1 developed autoimmune hemolytic anemia. Antinuclear antibodies were associated with the female sex (odds ratio, 3.166; 95% confidence interval, 1.167-8.585; P = 0.024) and with papulosquamous or butterfly rash (odds ratio, 10.016; 95% confidence interval, 1.708-58.725; P = 0.011).Conclusions The cumulative incidence of antinuclear antibodies was 56.8% after 24 months in this cohort of infliximab-treated Crohn's disease patients. Antinuclear antibodies persisted up to 1 year after the last infusion, and only a few patients became seronegative. Two patients developed drug-induced lupus erythematosus. Antinuclear antibodies were associated with the female sex and skin manifestations.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0016-5085(03)00701-7

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 31 references

Research works printed but not linked: 3

  1. Charles, 2000, Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha, Arthritis Rheum, 43, 2383, 10.1002/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D · doi:10.1002/1529-0131(200011)43:11<2383::aid-anr2>3.0.co;2-d
  2. Brandt, 2000, Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab, Arthritis Rheum, 43, 1346, 10.1002/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E · DOI · Paper page
  3. Via, 1996, Administration of anti-tumor necrosis factor (TNF) monoclonal antibody (MAB) induces lupus-like auto-immunity in the parent-into-f1 (P-F1) model of acute graft versus host disease (GVHD), Arthritis Rheum, 39, S108

Cited by

See all 327

Metadata

Authors
Vermeire, S., Noman, M., Van Assche, G., Baert, F., Van Steen, K., Esters, N., Joossens, S., Bossuyt, X., & Rutgeerts, P.
Affiliations
Universitair Ziekenhuis Leuven (BE)
Corresponding author
Rutgeerts, Paul
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2003-07
Volume
125
Issue
1
Pages
32-39
ISSN
0016-5085 (ISSN-L)
OpenAlex
W1976546496
Cited by
327
References
31
Citations by year
2025: 7 · 2024: 5 · 2023: 6 · 2022: 3 · 2021: 10 · 2020: 2 · 2019: 11 · 2018: 4 · 2017: 11 · 2016: 10 · 2015: 17 · 2014: 7 · 2013: 13 · 2012: 17
FWCI
17.15
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Gastroenterology (publishedVersion)
  • PubMed (publishedVersion)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion)
  • Document Server@UHasselt (UHasselt) (submittedVersion)
  • Open Repository and Bibliography (University of Liège) (submittedVersion)
Topics
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
Keywords
immunoglobulins, infliximab, Crohn's disease, anti-TNF therapy, drug-induced lupus, autoimmune hemolytic anemia, anti-histone antibodies, anti-dsDNA antibodies, single-stranded DNA antibodies, butterfly rash, sex differences, adverse drug reactions
MeSH terms
Infliximab, Adult, Antibodies, Monoclonal, Antibodies, Antinuclear, Crohn Disease, DNA, Female, Follow-Up Studies, Gastrointestinal Agents, Humans, Male, Prospective Studies, Tumor Necrosis Factor-alpha

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Autoimmunity associated with anti-tumor necrosis factor α treatment in Crohn’s disease: a prospective cohort study. https://app.cochat.ai/papers/10.1016/s0016-5085(03)00701-7
The paper
Vermeire, S., Noman, M., Van Assche, G., Baert, F., Van Steen, K., Esters, N., Joossens, S., Bossuyt, X., & Rutgeerts, P. (2003). Autoimmunity associated with anti-tumor necrosis factor α treatment in Crohn’s disease: a prospective cohort study. Gastroenterology. https://doi.org/10.1016/s0016-5085(03)00701-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.